FDA Grants Breakthrough Therapy Designation to Huahui Health’s Libevitug (HH-003) for treatment of chronic Hepatitis D virus infection

Posted on by

BEIJING, Nov. 18, 2024 /PRNewswire/ — Huahui Health, a clinical-stage biotechnology company focused on discovering and developing novel therapies in the areas of viral hepatitis, hepatology, and oncology, today announced that its investigational hepatitis D and B drug candidate,…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.